Breastfeeding with Qelbree

Qelbree is the first ADHD treatment to meet the 2019 FDA guidance for clinical lactation studies

If you have a young child or are planning to have a baby and breastfeed, it’s important to know certain information about your medications and to discuss options with your healthcare provider.

A medical study of 15 healthy lactating women receiving Qelbree  (600 mg/day for 3 days) found the transfer of Qelbree into breast milk was low.*

*This study did not specifically evaluate the effects of viloxazine on breastfed infants or milk production, nor are there additional data regarding these effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Qelbree and any potential adverse effects on the breastfed child from Qelbree or from the underlying maternal condition.

Transfer of Qelbree into breast milk is low*

Meet with your healthcare provider to discuss how Qelbree can help support your ADHD symptoms—and if it’s the right choice for you and your family.

Talk to your healthcare provider

Get a free, personalized questionnaire to help inform your conversation.

Create discussion guide

Get the Qelbree Savings Card

Qualified patients may pay as little as $20 per prescription.^†

Get the card

Frequently asked questions

Find answers to common questions about Qelbree and ADHD.

See FAQs

^†Terms and Conditions

This offer is good for most commercially insured and cash-paying patients purchasing Qelbree® and may not be used for any other product. Maximum benefits and quantity of capsules may apply. This offer is not valid for prescriptions purchased under Medicaid, Medicare, or other federal or state programs (such as medical assistance programs). Offer not valid where prohibited by law, taxed, or restricted. It is not transferable and may not be combined with any other offer. The amount of the rebate cannot exceed the patient’s actual out-of-pocket expenses. Offer must be presented along with a valid prescription for Qelbree at the time of purchase. By enrolling into this program you are consenting to the collection and use of certain personal information, including your phone number and/or email address and elements of pharmacy claim information. This information will be collected and used by service providers of Supernus Pharmaceuticals, Inc. (“Supernus”), in order to administer this program. This information is not provided to Supernus directly. If you do not consent, please do not enroll into the program. If you require additional assistance, please call 1-866-398-0833. Supernus reserves the right to rescind, revoke, or amend this offer without notice at any time.

INDICATION

Qelbree^® (viloxazine extended-release capsules) is a prescription medicine used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment [read more] or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. [read more] Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Medication Guide, including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE